Actively Recruiting
Phase 1b Study of Azenosertib Combined With Chemotherapy or Bevacizumab for Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
Led by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Updated on 2026-04-07
172
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, early clinical effects, and how the body processes azenosertib ZN-c3 when combined with other drugs in patients with advanced ovarian, peritoneal, or fallopian tube cancer. This Phase 1b open-label study includes patients with platinum-resistant or maintenance therapy contexts, aiming to understand dosing and treatment combinations better. The study has two parts Part 1 assessed azenosertib with chemotherapy drugs including carboplatin, pegylated liposomal doxorubicin PLD, paclitaxel, and gemcitabine in platinum-resistant cases. Part 2 explores azenosertib with bevacizumab as first- or second-line maintenance therapy after platinum chemotherapy. Dose escalation and expansion phases determine recommended doses and evaluate safety. Participants will receive study treatments in combination regimens and undergo regular assessments over about one year. Researchers monitor safety, side effects, and drug levels, aiming to find the maximum tolerated dose and recommended dosing. The study includes clinical evaluations, laboratory tests, and ongoing monitoring of patient response and tolerability throughout the study period.
CONDITIONS
Brief Title
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Research Team
K
K-Group, Beta, Inc., a subsidiary of Zentalis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
